http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Review : Production of Biopharmaceuticals in E. coli: Current Scenario and Future Perspectives
( Mohammed N. Baeshen ),( Ahmed M. Al Hejin ),( Roop S. Bora ),( Mohamed M. M. Ahmed ),( Hassan A. I. Ramadan ),( Kulvinder S. Saini ),( Nabih A. Baeshen ),( Elrashdy M. Redwan ) 한국미생물 · 생명공학회 2015 Journal of microbiology and biotechnology Vol.25 No.7
Escherichia coli is the most preferred microorganism to express heterologous proteins for therapeutic use, as around 30% of the approved therapeutic proteins are currently being produced using it as a host. Owing to its rapid growth, high yield of the product, costeffectiveness, and easy scale-up process, E. coli is an expression host of choice in the biotechnology industry for large-scale production of proteins, particularly non-glycosylatedproteins, for therapeutic use. The availability of various E. coli expression vectors and strains, relatively easy protein folding mechanisms, and bioprocess technologies, makes it very attractive for industrial applications. However, the codon usage in E. coli and the absence ofpost-translational modifications, such as glycosylation, phosphorylation, and proteolytic processing, limit its use for the production of slightly complex recombinant biopharmaceuticals. Several new technological advancements in the E. coli expression system to meet the biotechnology industry requirements have been made, such as novel engineered strains,genetically modifying E. coli to possess capability to glycosylate heterologous proteins an express complex proteins, including full-length glycosylated antibodies. This review summarizes the recent advancements that may further expand the use of the E. coli expression system to produce more complex and also glycosylated proteins for therapeutic use in the future.